Acute Hepatitis A Causing Severe Hemolysis and Renal Failure in Undiagnosed Glucose-6-Phosphate Dehydrogenase Deficient Patient: A Case Report and Review of the Literature

Iman Abutineh,1 Kyle Kreitman,2 Jiten P. Kothadia,2 Bilal Ali,2 Richa Jain,3 Ian Clark,3 Benedict J. Maliakkal,2 and Satheesh P. Nair2

1Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA
2Methodist University Hospital, James D. Eason Transplant Institute, University of Tennessee Health Science Center, Memphis, TN, USA
3Department of Pathology, Memphis Pathology Group, University of Tennessee Health Science Center, Methodist University Hospital, Memphis, TN, USA

Correspondence should be addressed to Kyle Kreitman; kkreitma@uthsc.edu

Received 1 March 2021; Revised 22 April 2021; Accepted 24 May 2021; Published 3 June 2021

Academic Editor: Haruki Komatsu

Copyright © 2021 Iman Abutineh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infection with hepatitis A virus is usually a self-limited illness that rarely results in fulminant liver failure. Severe hemolysis is a known complication of acute viral hepatitis [2, 3]. In a few cases, patients may present with severe hemolysis, which is more frequent in patients with coexisting glucose-6-phosphate dehydrogenase (G6PD) deficiency [4–7]. It has been postulated that viral infection itself can cause severe hemolysis in a patient with G6PD deficiency. In addition, the administration of certain drugs and particular foods may aggravate the condition [2].

A mild to moderate degree of hemolysis is a known complication of acute viral hepatitis. In a few cases, patients may present with severe hemolysis, which is more frequent in patients with coexisting glucose-6-phosphate dehydrogenase (G6PD) deficiency [2–9]. It has been postulated that viral infection itself can cause severe hemolysis in a patient with G6PD deficiency. In addition, the administration of certain drugs and particular foods may aggravate the condition [2]. It has also been noted that G6PD deficiency impedes the repair of the damaged hepatocytes and can lead to fulminant hepatitis and liver failure in patients with acute viral hepatitis [10, 11]. Here, we describe a patient with undiagnosed G6PD deficiency who presented with hyperbilirubinemia, severe hemolysis, and acute renal failure precipitated by acute hepatitis A infection.

2. Case Report

A 55-year-old African American male with a medical history of hypertension, hyperlipidemia, chronic hepatitis B, and well-controlled HIV on ART presented to the hospital with a one-week history of fatigue, fever, myalgias, shortness of breath, and dark-colored urine. He denied any history of alcohol, illicit drug use, or family history of liver disease.

On physical exam, he had scleral icterus and mild lower abdominal pain without guarding, rebound, or rigidity. He was alert and oriented without focal deficit or asterixis. He had no ascites. Vital signs were within normal limits. Lab work was significant for creatinine at 6.38 mg/dL (0.7–1.3), BUN 48 mg/dL (7–18), total bilirubin 51.8 mg/dL (0.2–1),
direct bilirubin 40.4 mg/dL (≤0.2), lactate dehydrogenase 2678 unit/L (87–241), haptoglobin <7.7 mg/dL, alkaline phosphatase 195 unit/L, AST 216 unit/L (15–37), ALT 6,244 unit/L (16–61), lactic acid 5.5 mmol/L (0.4–2), WBC 16.6 thou/mcL (4.2–10.2), hemoglobin 7.5 g/dL (12.8–16.4), platelet 344 × 10^9/microL (150–400), and INR 1.6 (0.8–1). His model for end-stage liver disease (MELD) score was 40. Urine drug screen, creatinine, and alcohol level were negative. Serologic studies for *Treponema pallidum*, cytomegalovirus, Epstein–Barr virus, herpes simplex virus, and parvovirus were negative. Influenza and COVID-19 PCR were negative. The hepatitis panel was positive for hepatitis A IgM, hepatitis A total antibody, and hepatitis B core IgG antibody. Hepatitis C antibody, hepatitis E IgG/IgM, and HBV DNA were negative. His autoimmune markers including antinuclear antibody, antihistone muscle antibody, antimitochondrial antibody, and myeloperoxidase autoantibody were negative. Serum ceruloplasmin was also negative. Erythrocyte G6PD level was normal due to acute hemolysis. A computed tomography (CT) scan of the abdomen and pelvis showed normal appearing liver with nondilated bile ducts and patent hepatic vasculature. A transthoracic echocardiogram (TTE) showed LVEF 60–65% with normal wall motion, no diastolic dysfunction, valvular disease, or thrombus.

The patient was treated empirically with antibiotics and intravenous fluids. Patient continued to be oliguric and hemodialysis was initiated. Peripheral smear showed fragmented erythrocytes, spherocytes, bite cells, and target cells indicative of hemolysis. Fibrinogen was normal, and Coomb’s test was negative. Liver biopsy showed cholestatic hepatitis with areas of resolving necrosis (Figure 1). Renal biopsy showed acute tubular injury with bilirubin and hemoglobin casts (Figure 2). The patient was initially listed for transplant but clinically improved with supportive measures alone. Over the next few weeks, patient’s liver functions test and hemolysis labs steadily improved (Figures 3 and 4). He was discharged to a rehab facility and has since followed up in our clinic. His most recent liver function tests, 3 months after hospitalization, are normal. Erythrocyte G6PD is 3.3 U/g Hb, confirming the diagnosis of G6PD deficiency. His renal function also improved, and he is no longer on dialysis.

**3. Discussion**

Hepatitis A is the most common cause of viral hepatitis worldwide, generally causing a mild self-limited illness akin to other foodborne illnesses. Chronic sequelae are rare, and mortality related to hepatitis A accounts for only 0.5% of deaths secondary to viral hepatitis [10]. However, recent data suggest a dramatic increase in the number of outbreaks occurring worldwide. The recent CDC morbidity and mortality report warn of a considerable increase in hepatitis A in the United States, with cases climbing by 294% in 2016–2018 compared to the country’s nadir in 2013–2015 [12, 13]. Acute liver failure secondary to hepatitis A is rare, but with higher rates in older adults >40 years of age or those with chronic liver disease [10, 14]. Hemolytic anemia has been associated with viral hepatitis, but the degree is usually mild to moderate [3]. When the disease course is complicated by severe hemolysis, a diagnosis in addition to hepatitis should be sought out [3, 15]. A more common occurrence seemed to be the finding of underlying G6PD deficiency in patients who developed severe hemolysis [2–4, 6–9, 15].

To our knowledge, this is the first reported case of severe hemolysis and renal failure precipitated by acute HAV in an undiagnosed G6PD deficient and HIV-positive patient in the United States. G6PD deficiency is the most common human enzyme defect, affecting more than 400 million people worldwide. This X-linked hereditary defect impairs catalysis of the first step in the pentose phosphate pathway, which is crucial for the production of NADPH, protecting cells from oxidative stress, and regenerating glutathione for reduction of reactive oxygen species [16, 17]. While usually a clinically silent disorder, certain stressors, including drugs (particularly primaquine or trimethoprim-sulfamethoxazole), ingestion of food (fava beans, bitter melon, blueberries, and falafel), or viral infection can trigger an acute hemolytic crisis [18–20]. The global prevalence of the disorder is 4.9%, with African and Mediterranean descent at the highest risk [21], an estimated 10% of black Americans and as high as 70% of Kurdish Jews may carry the mutation [16].

Despite a high prevalence of G6PD deficiency in the African American population, there are no current universal screening guidelines for the disease. However, evidence suggests that these patients have a more complicated course when infected by hepatitis A than a non-G6PD deficient patient [3, 5, 22]. In a retrospective study by Gotsman and Muskat of patients with acute hepatitis A admitted between 1980 and 1999, those with G6PD deficiency demonstrated a more severe clinical course with severe hemolysis and higher bilirubin level [5]. It has been hypothesized that G6PD deficient hepatocytes have reduced levels of glutathione, thereby causing an accumulation of free radicals and delayed hepatocyte repair with viral insult. There is ongoing discussion regarding the utility of blood transfusions or plasmapheresis in cases with severe hemolysis to prevent long-standing complications including renal failure [8].

On review of literature, there are 80 cases related to viral hepatitis, and G6PD deficiency causing severe hemolysis has been reported (Table 1) [2–9, 23–35]. The patient’s median age was 19.5 years (IQR: 14.25–35). Among these patients, 32 had hepatitis A, 19 had hepatitis E, and 29 had unspecified viral hepatitis as a precipitating cause for severe hemolysis. 22.5% (18/80) of the patients had renal failure as a complication, and of that, 12 were treated with dialysis. One patient was treated with plasmapheresis. Of the 80 total patients, 72 (90%) made a full recovery, while 8 died of complications from renal/liver failure, seizures, sepsis, and cerebral hemorrhage. Our case was an immunocompromised patient with HIV treated with empiric antibiotics, blood transfusion, and hemodialysis with subsequent clinical improvement.

With a large population at risk and an alarming rise in acute HAV cases in the United States, it is of utmost importance for clinicians to be cognizant of typical and atypical features of the infection. Although most acute HAV cases
Figure 1: (a) Liver biopsy (H&E, x40) showing bridging necrosis and collapse of parenchyma with cholestasis and sparse inflammatory infiltrate rich in lymphocytes and plasma cells ((b) inset x200). (c) A trichrome stain (x20) showing lack of fibrosis supporting acute nature of the illness.

Figure 2: (a) Renal biopsy showing tubular casts comprising of hemoglobin (hemoglobin immunostained (b)) and bile pigment (Fouchet stained (c)). Glomeruli and vasculature were within normal limits.
will resolve with supportive care alone, those with underlying G6PD deficiency are at an increased risk for developing severe intravascular hemolysis, marked hyperbilirubinemia, and increased risk of developing acute renal failure. Oxidant medications and nephrotoxins should be avoided. Treatment is generally supportive, but corticosteroids and plasma exchange can be considered in certain instances [15]. We recommend the hepatitis A vaccine in all patients with underlying G6PD deficiency. Ultimately, a high clinical suspicion and early recognition of patients at risk for severe manifestations of viral hepatitis can alter the course of the disease and aid in preventing chronic sequelae.

**Figure 3:** Changes in AST, ALT, LDH, and T-Bil during hospitalization are plotted from admission at days 1–25.

**Figure 4:** Changes in INR, hemoglobin, and reticulocyte counts during hospitalization are plotted from admission at days 1–25.
| Year  | Author               | Number of cases | Age (y) | Sex | Presenting symptoms                  | Geographic region | Cause of viral hepatitis | Presence of renal failure | Treatment                                                                 | Need for transplant | Outcome                        |
|-------|----------------------|-----------------|---------|-----|--------------------------------------|-------------------|-------------------------|--------------------------|---------------------------------------------------------------------------|---------------------|---------------------------------|
| 1966  | Salen [23]           | 3               | 38, 28, 39 | F, M, M | Fever, anorexia, and dark urine | USA               | Did not specify         | Yes (1 patient)           | F: peritoneal dialysis, prednisone 40mg qday; M-28: IVF; M-39: IVF and blood transfusion | No                  | Full recovery                   |
| 1969  | Clearfield et al. [4] | 3               | 29, 31, 24 | M, M, M | Myalgia, nausea, pruritis, dark urine, and jaundice | USA               | Did not specify         | No                       | Supportive care for all three patients                                      | No                  | Full recovery                   |
| 1975  | Chan and Todd [3]    | 18              | N/A      | N/A | Fever and jaundice                  | Hong Kong         | Did not specify         | No                       | Supportive care for all 18 patients                                       | No                  | 15 had full recovery and 3 died from renal failure and hemolysis          |
| 1985  | Agarwal et al. [24]  | 5               | 9, 19, 10, 10, 8 | 5 M | Fever, jaundice, and vomiting       | India             | Did not specify         | Yes (2 patients)           | 4 patients required blood transfusions and 1 patient required peritoneal dialysis, blood transfusions, and antibiotics | No                  | 4 had full recovery and 1 died of liver and renal failure                 |
| 2001  | Gotsman Muszkat [5]  | 18              | Average 15.1 | 13 M, 5 F | Fever and jaundice                  | Israel            | A                       | No                       | 3 patients required blood transfusion, IVF fluids, and antibiotics. 15 patients required supportive care | No                  | Full recovery                   |
| 2002  | Abid and Khan [25]   | 5               | 26,16, 14, 22, 35 | 5 M | Fatigue, fever, jaundice, and vomiting | Pakistan          | E                       | Yes (5 patients)          | Supportive care for all 5 patients and 2 patients required hemodialysis        | No                  | Full recovery                   |
| 2003  | Monga et al. [26]    | 1               | 35       | M   | Fever, abdominal pain, fatigue, jaundice, and dark urine | India             | E                       | No                       | Supportive care                                                        | No                  | Full recovery                   |
| 2008  | Ozbay Hosnus et al. [8] | 2          | 10, 5 | M, F | Jaundice, emesis, and abdominal pain | Europe            | A                       | Yes (1 patient)           | Male: IVF, blood transfusion, and plasmapheresis; female: antibiotic therapy, vitamin K, lactulose, IVF, and blood transfusion | No                  | Full recovery                   |
| 2009  | Thapa et al. [27]    | 1               | 7        | M   | Jaundice                            | India             | E                       | No                       | Supportive care                                                        | No                  | Full recovery                   |
| 2011  | Somani et al. [29]   | 1               | 17       | M   | Fever, abdominal pain, anorexia, jaundice, and dark urine | India             | E                       | Yes                      | Supportive care                                                        | No                  | Full recovery                   |
| 2011  | Au et al. [28]       | 1               | 54       | M   | Jaundice, cyanosis, and confusion   | Hong Kong         | E                       | Yes                      | Hemodialysis                                                          | No                  | Died of cerebral hemorrhage     |
| 2012  | Jain et al [6]       | 10              | Average 16.1 | 8 M, 2 F | N/A                                | India             | A, E                    | No                       | Supportive care                                                        | No                  | Full recovery                   |
| Year | Author | Number of cases | Age (y) | Sex  | Presenting symptoms | Geographic region | Cause of viral hepatitis | Presence of renal failure | Treatment | Need for transplant | Outcome |
|------|--------|----------------|---------|------|---------------------|-------------------|------------------------|--------------------------|-----------|---------------------|---------|
| 2012 | Wing-Yan and Chan [34] | 2 | 53, 54 | M | Right upper quadrant pain and flu-like symptoms | Hong Kong | E | Yes (1 patient) | Blood transfusion and hemodialysis | No | 53-year-old died of seizures and sepsis. 54-year-old died of renal and liver failure |
| 2014 | Tomar et al. [31] | 1 | 15 | M | Fever, jaundice, dark urine, nausea, fatigue, and decreased PO intake | India | E | Yes | Blood transfusion and hemodialysis | No | Full recovery |
| 2015 | Dea [30] | 1 | 20 | M | Fever, jaundice, and dark urine | India | A | No | Supportive care | No | Full recovery |
| 2016 | Karki et al. [32] | 1 | 48 | M | Jaundice, dark urine, fever, and confusion | India | E | Yes | Blood transfusion, hemodialysis, and antibiotics | No | Full recovery |
| 2017 | Moiz and Ali [7] | 1 | 10 | F | Fever, abdominal pain, and lethargy | Pakistan | A | No | Supportive care | No | Full recovery |
| 2017 | Ahmad et al. [33] | 1 | 28 | M | Jaundice and abdominal pain | Pakistan | E | Yes | Blood transfusion and hemodialysis | No | Full recovery |
| 2018 | Sharma et al. [9] | 1 | 39 | M | Fever, jaundice, and dark urine | India | A | Yes | Blood transfusion and intermittent hemodialysis, IVF, ventilation, antibiotics, continuous renal replacement, and plasma and blood transfusion | No | Full recovery |
| 2019 | Bajpai et al. [2] | 1 | 16 | M | Fever, jaundice, and dark urine | India | A | Yes | Blood transfusion and hemodialysis | No | Full recovery |
| 2020 | Bajpai et al. [2] | 2 | 19, 15 | M | Jaundice, nausea, and vomiting | Pakistan | E | No | IVF and blood transfusion | No | 19-year-old died from liver failure. 15-year-old made a full recovery |
| 2020 | Abutineh et al. (present case) | 1 | 55 | M | Fatigue, fever, malaise, jaundice, and abdominal pain | US | A | Yes | IVF, antibiotics, blood transfusion, and hemodialysis | No | Full recovery |
4. Conclusions
While this may be the first reported case with an HIV-positive patient in the United States, the phenomenon is one that has been reported in foreign literature for decades. With a high prevalence of G6PD deficiency and an increased incidence of hepatitis A in the past few years, it is imperative for clinicians to be mindful of the potential complications to prevent chronic sequelae and adverse outcomes. In conclusion, intravascular hemolysis due to G6PD deficiency should be considered in patients with acute hepatitis A infection who present with marked hyperbilirubinemia and renal failure.

Abbreviations
ART: Antiretroviral therapy 
ATN: Acute tubular necrosis
G6PD: Glucose-6-phosphate dehydrogenase
HBV: Hepatitis B virus 
HIV: Human immunodeficiency virus.

Disclosure
This case report was presented at ACG 2020.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Drafting the case report and acquisition of available literature were carried out by Iman Abutineh, MD and Kyle Kreitman, DO. Drafting the case report and critical revision of the manuscript for important intellectual content were carried out by Jiten P. Kothadia, MD. Histopathology images were provided and the manuscript was reviewed by Richa Jain, MD, Ian Clark MD. The manuscript was reviewed by Satheesh P. Nair, MD, Benedict J. Maliakkal, MD, and Bilal Ali, MD.

References
[1] A. H. Havelaar, “World Health Organization Global estimates and regional comparisons of the burden of foodborne disease in 2010,” PLoS Medicine, vol. 12, no. 12, Article ID e1001923, 2015.
[2] M. Bajpai, B. Kakkar, and D. Patale, “Role of high-volume plasma exchange in a case of a G6PD deficient patient presenting with HAV related acute liver failure and concomitant acute renal failure,” Transfusion and Apheresis Science, vol. 58, no. 6, Article ID 102677, 2019.
[3] T. K. Chan and D. Todd, “Haemolysis complicating viral hepatitis in patients with glucose-6-phosphate dehydrogenase deficiency,” Bmjr, vol. 1, no. 5950, pp. 131–133, 1975.
[4] H. R. Clearfield, J. J. Brody, and H. J. Tumen, “Acute viral hepatitis, glucose-6-phosphate dehydrogenase deficiency, and hemolytic anemia,” Archives of Internal Medicine, vol. 123, no. 6, pp. 689–691, 1969.
[5] I. Gotsman and M. Muszkat, “Glucose-6-phosphate dehydrogenase deficiency is associated with increased initial clinical severity of acute viral hepatitis A,” Journal of Gastroenterology and Hepatology, vol. 16, no. 11, pp. 1239–1243, 2001.
[6] A. K. Jain, S. Sircar, M. Jain, S. Adkar, C. Waghmare, and F. Chalwala, “Increased morbidity in acute viral hepatitis with glucose-6-phosphate dehydrogenase deficiency,” Indian Journal of Gastroenterology, vol. 32, no. 2, pp. 133–134, 2013.
[7] B. Moza and S. A. Ali, “Pulmonary hemolysis in glucose-6-phosphate dehydrogenase deficiency,” Clinical Case Reports, vol. 6, no. 1, pp. 224–225, 2018.
[8] F. Ozbay Hosnut, F. Orzay, U. Selda Bayrakci, Z. Avci, and N. Ozbek, “Etiology of hemolysis in two patients with hepatitis A infection: glucose-6-phosphate dehydrogenase deficiency or autoimmune hemolytic anemia,” European Journal of Pediatrics, vol. 167, no. 12, pp. 1435–1439, 2008.
[9] D. Sharma, O Singh, D Juneja, A Goel, S. K Garg, and S Shekhar, “Hepatitis A virus-induced severe hemolysis complicated by severe glucose-6-phosphate dehydrogenase deficiency,” Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine, vol. 22, no. 9, pp. 670–673, 2018.
[10] E. C. Shin and S. H. Jeong, “Natural history, clinical manifestations, and pathogenesis of hepatitis A,” Cold Spring Harbor Perspectives in Medicine, vol. 8, no. 9, 2018.
[11] A. Serious Hepatitis, “An analysis of patients hospitalized during an urban epidemic in the United States,” Annals of Internal Medicine, vol. 128, no. 2, pp. 111–114, 1998.
[12] N. P. Nelson, “Prevention of hepatitis A virus infection in the United States,” Recommendations of the Advisory Committee on Immunization Practices, vol. 2020, 2020.
[13] M. A. Foster, M. G. Hofmeister, B. A. Kupronis et al., “Increase in Hepatitis A virus infections-United States, 2013–2018,” MMWR Morbidity and Mortality Weekly Report, vol. 68, no. 18, pp. 413–415, 2019.
[14] S. M. Lemon, “Type a viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention,” Journal of Hepatology, vol. 17, 2017.
[15] “Acute hemolytic anemia complicating viral hepatitis in patients with glucose-6-phosphate dehydrogenase deficiency,” Annals of Internal Medicine, vol. 65, no. 6, pp. 1210–1220, 1966.
[16] E. Beutler, “G6PD deficiency,” Blood, vol. 84, no. 11, pp. 3613–3636, 1994.
[17] M. Cappellini and G. Fiorelli, “Glucose-6-phosphate dehydrogenase deficiency,” The Lancet, vol. 371, no. 9606, pp. 64–74, 2008.
[18] L. Luzzatto and P. Arrese, “Favism and glucose-6-phosphate dehydrogenase deficiency,” New England Journal of Medicine, vol. 378, no. 1, pp. 60–71, 2018.
[19] T. Babu, G. M. Panachiyil, J. Sebastian, and M. D. Ravi, “Probable blueberry-induced haemolysis in a G6PD deficient child: a case report,” Nutrition and Health, vol. 25, no. 4, pp. 303–305, 2019.
[20] S. N. Stone, K. V. Reisig, H. L. Saffel, and C. M. Miles, “Management of athletes with G6PD deficiency: does missing an enzyme mean missing more games?” Sports Health: A Multidisciplinary Approach, vol. 12, no. 2, pp. 149–153, 2020.
[21] E. T. Nkhoma, C. Poole, V. Vannappagari, S. A. Hall, and E. Beutler, “The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis,” Blood Cells, Molecules, and Diseases, vol. 42, no. 3, pp. 267–278, 2009.
[22] C. A. Kattamis and F. Tjoartatou, “The hemolytic process of viral hepatitis in children with normal or deficient glucose-6-
phosphate dehydrogenase activity,” *The Journal of Pediatrics*, vol. 77, no. 3, pp. 422–430, 1970.

[23] G. Salen, “Acute hemolytic anemia complicating viral hepatitis in patients with glucose-6-phosphate dehydrogenase deficiency,” *Annals of Internal Medicine*, vol. 65, no. 6, pp. 1210–1220, 1966.

[24] R. K. Agarwal, A. Moudgil, K. Kishore, R. N. Srivastava, and R. K. Tandon, “Acute viral hepatitis, intravascular haemolysis, severe hyperbilirubinaemia and renal failure in glucose-6-phosphate dehydrogenase deficient patients,” *Postgraduate Medical Journal*, vol. 61, no. 721, pp. 971–975, 1985.

[25] S. Abid and A. H. Khan, “Severe hemolysis and renal failure in glucose-6-phosphate dehydrogenase deficient patients with hepatitis E,” *The American Journal of Gastroenterology*, vol. 97, no. 6, pp. 1544–1547, 2002.

[26] A. Monga, R. P. Makkar, A. Arora, S. Mukhopadhyay, and A. K. Gupta, “Case report: acute hepatitis E infection with co-existent glucose-6-phosphate dehydrogenase deficiency,” *Canadian Journal of Infectious Diseases*, vol. 14, no. 4, pp. 230-231, 2003.

[27] R. Thapa, S. Pramanik, B. Biswas, and D. Mallick, “Hepatitis E virus infection in a 7-year-old boy with glucose 6-phosphate dehydrogenase deficiency,” *Journal of Pediatric Hematology/Oncology*, vol. 31, no. 3, pp. 223-224, 2009.

[28] W. Y. Au, C.-W. Ngai, W.-M. Chan, R. Y. Y. Leung, and S.-C. Chan, “Hemolysis and methemoglobinemia due to hepatitis E virus infection in patient with G6PD deficiency,” *Annals of Hematology*, vol. 90, no. 10, pp. 1237-1238, 2011.

[29] S. K. Somani, “Hepatitis e virus infection leads to severe hemolysis in glucose-6-phosphate dehydrogenase deficiency patients,” 2011.

[30] B. Dea, “Severe hemolysis as the first manifestation of acute hepatitis A in an adult with G6PD deficiency and positive ANA,” *American Journal of Medical Case Reports*, vol. 3, pp. 158-159, 2015.

[31] L. R. Tomar, A. Aggarwal, P. Jain, S. Rajpal, and M. P. Agarwal, “Acute viral hepatitis E presenting with haemolytic anaemia and acute renal failure in a patient with glucose-6-phosphate dehydrogenase deficiency,” *Tropical Doctor*, vol. 45, no. 4, pp. 245-246, 2015.

[32] P. Karki, S Malik, B Mallick, V Sharma, and S. S Rana, “Massive Hemolysis causing renal failure in acute hepatitis E infection,” *Journal of Clinical and Translational Hepatology*, vol. 4, no. 4, pp. 345–347, 2016.

[33] B. S. Ahmad, A Ahmad, S Jamil, S. A Abubakar Mohsin Ehsanullah, and A Munir, “Severe haemolysis and renal failure precipitated by hepatitis E virus in G6PD Deficient patient: a case report,” *JPMA. The Journal of the Pakistan Medical Association*, vol. 68, pp. 1397–1399, 2018.

[34] A. Wing-Yan and S. Chan, “Association between glucose 6-phosphate dehydrogenase (G6PD) deficiency and fatal outcome,” *Singapore Medical Journal*, vol. 53, no. 2, pp. 148-149, 2012.

[35] L. Kamani, H. Shaikh, and A. K. Khemchandani, “Fulminant hepatic failure in glucose-6-phosphate dehydrogenase (G6PD) deficient patients caused by hepatitis E infection: a single disease with different spectrums,” *Cureus*, vol. 12, no. 12, Article ID e12276, 2020.